NeuroPace Q3 revenue misses analyst estimates, dragged by account-level issues

By Reuters News


Overview

  • U.S. epilepsy device maker's Q3 revenue declined 1% yr/yr, missing analyst expectations

  • Company narrowed Q3 net loss compared to prior year

  • NeuroPace cut full-year 2026 revenue guidance, citing account-level disruptions and field changes


Outlook

  • NeuroPace cuts 2026 revenue guidance to $91 mln-$92 mln from $99.5 mln-$101.5 mln

  • Company raises 2026 non-GAAP gross margin outlook to 83.0%-83.5% from 82.0%-83.0%

  • NeuroPace lowers 2026 non-GAAP operating expense forecast to $85 mln-$86 mln from $90 mln-$92 mln


Result Drivers

  • ACCOUNT-LEVEL DISRUPTIONS - Co said Q3 revenue shortfall was concentrated in several large accounts and reflected isolated account-level issues and field organization changes

  • COMMERCIAL EXECUTION - Co said it is taking action to improve commercial execution and return to historical growth rates

  • LOWER PERSONNEL COSTS - Decline in operating expenses was largely due to decreased personnel-related expenses, including sales commissions and variable compensation


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$23.10 mln

$27.16 mln (10 Analysts)

Q3 Loss Per Share

$0.10

Q3 Net Loss

$3.30 mln

Q3 Gross Profit

$19.47 mln

Q3 Operating Expenses

$21.55 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for NeuroPace, Inc. is $20.00, about 59.7% above its November 11 closing price of $12.52


Reuters Recommended Reads

  • Nov 10 - Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth

  • Nov 10 - Surgical robotics firm Stereotaxis' Q3 revenue rises, but misses estimates

  • Nov 10 - QT Imaging Q3 revenue jumps 75% on scanner sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.